zanubrutinib

BeiGene’s Phase III Waldenström’s study misses mark, but with a possible silver lining

The Phase III study showed that BeiGene's Brukinsa outperformed AbbVie and J&J's Imbruvica on safety. An analyst wrote that FDA approval on that basis is unlikely, but off-label prescribing is possible. Brukinsa won approval for another blood cancer last month.

By Alaric DeArment

BioPharma

China’s BeiGene gets FDA breakthrough therapy designation for BTK inhibitor

While zanubrutinib showed a higher response rate in the same mantle cell lymphoma setting for which Imbruvica is approved, the Phase II study enrolled younger, less heavily pretreated patients than those in Imbruvica's pivotal trial.

By Alaric DeArment

Healthcare

Using Data to Help Healthcare Practices Succeed

A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.

By Relatient